HLA-C Matched NK Cells for Hematologic Malignancy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematologic cancers, such as acute lymphoblastic leukemia and chronic lymphocytic leukemia, face challenges due to limited access to HLA-matched donors and the risks associated with cord blood transplantation, including delayed hematopoietic recovery and graft-versus-host disease, necessitating alternative strategies to enhance the immune response against cancer cells.
Innovation Solution
Administration of therapeutically effective amounts of genetically engineered natural killer (NK) cells expressing specific killer immunoglobulin-like receptors (KIR) licensed for particular HLA-C genotypes, combined with chimeric antigen receptors (CARs) and interleukin-15, to target tumor antigens like CD19, while incorporating a suicide gene for safety, to enhance anti-tumor activity and minimize adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplantation is performed to treat hematologic cancers, then curative treatment is achieved, but access is limited due to lack of HLA-matched donors
Solution Approach 1:
The patent introduces NK cells as an intermediary therapeutic agent that can be derived from cord blood units without requiring HLA matching between donor and recipient. These NK cells serve as a mediator to provide graft-versus-leukemia effect while avoiding the limitation of donor availability, thus resolving the contradiction between curative efficacy and donor accessibility
Solution Approach 2:
The patent extracts and utilizes the graft-versus-leukemia effect from donor lymphocytes specifically through NK cells, separating this beneficial function from the limitations of full allogeneic stem cell transplantation. By focusing on NK cell transfer rather than complete HLA-matched transplantation, the therapy achieves curative effect without requiring broad HLA compatibility
2Adaptability or versatility
If cord blood transplantation is used to expand access to stem cell transplantation, then donor availability increases, but delayed hematopoietic recovery occurs leading to higher infection risks
Solution Approach 1:
The patent applies preliminary action by pre-expanding NK cells ex vivo before transplantation to achieve higher cell doses that can more rapidly reconstitute the recipient's immune system. This pre-preparation of NK cells with enhanced numbers and functionality addresses the delayed immune recovery issue while maintaining the advantage of using cord blood donors
Solution Approach 2:
The patent changes the parameter of NK cell dosage by implementing high-dose NK cell infusions (e.g., ≥1×10^6 NK cells/kg body weight). This parameter change accelerates hematopoietic recovery and reduces infection risk while preserving the benefit of expanded donor availability through cord blood units
3Reliability
If donor lymphocyte infusions are administered to eliminate minimal residual disease, then antileukemic immunity is augmented, but graft-versus-host disease occurs
Solution Approach 1:
The patent applies local quality by selecting NK cells with specific KIR receptor profiles that are locally optimized for recognizing and killing leukemia cells while having reduced capacity to attack host tissues. This selective matching of NK cell subsets provides targeted antileukemic activity with minimized GVHD risk
Solution Approach 2:
The patent uses cord blood-derived NK cells as a standardized product that can be cryopreserved and stored, creating a reusable therapeutic product that eliminates the need for repeated donor lymphocyte infusions. This single administration approach achieves durable antileukemic immunity without the cumulative GVHD risk associated with multiple DLI treatments
4Reliability
If NK cells are used to mediate graft-versus-leukemia effect, then immune response against cancer cells is enhanced, but lack of specific KIR-HLA matching reduces treatment efficacy
Solution Approach 1:
The patent applies dynamics by using polygenic KIR profiles in NK cells that can recognize multiple different HLA-C alleles. This dynamic recognition capability allows a single NK cell product to be effective across different HLA-C genotypes, eliminating the need for precise KIR-HLA matching while maintaining strong graft-versus-leukemia effect
Solution Approach 2:
The patent achieves universality by selecting NK cells that express multiple KIR receptors (including both group 1 and group 2 KIRs) that can bind to various HLA-C variants. This multi-functional NK cell population can recognize and kill leukemia cells regardless of the recipient's specific HLA-C genotype, providing broad-spectrum efficacy without requiring precise matching
Data Source
AI summary
The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.